Video

Dr. Van Veldhuizen on Frontline Immunotherapy for Kidney Cancer

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

The nivolumab (Opdivo) and ipilimumab (Yervoy) combination has been exciting, Van Veldhuizen says, because it resulted in some complete responses in clinical trials. The tolerability in some patients remains an unanswered question, so performance status and age should play a role in deciding if this regimen is the right treatment. An exploratory analysis has also suggested that PD—L1-positive patients with intermediate- or high-risk disease will benefit the most from immunotherapy. Therefore, Van Veldhuizen says, PD–L1 status could be a good biomarker in deciding if immunotherapy or a tyrosine kinase inhibitor (TKI) is better for a patient.

Cabozantinib (Cabometyx) and pazopanib (Votrient) have emerged as effective TKIs for patients who are ineligible for immunotherapy.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center